The importance of NKG2D-mediated response of NK cells against cancer has been demonstrated by immunogenetic, clinical and experimental studies12, also corroborated by the evidence that most anticancer drugs, including antimetabolic agents, antitumor antibiotics, and histone deacetylase inhibitors (HDACi), upmodulate NKG2DLs on tumor cells7. The gene discussed is KLRK1; the disease is cancer.